Day: July 10, 2025

RUSTON, La., July 10, 2025 (GLOBE NEWSWIRE) — Origin Bancorp, Inc. (NYSE: OBK) (“Origin”), the financial holding company for Origin Bank, plans to issue second quarter 2025 results after the market closes on Wednesday, July 23, 2025, and hold a conference call to discuss such results on Thursday, July 24, 2025, at 8:00 a.m. Central Time (9:00 a.m. Eastern Time). The conference call will be hosted by Drake Mills, Chairman, President and CEO of Origin, William J. Wallace, IV, Chief Financial Officer of Origin, and Lance Hall, President and CEO of Origin Bank. Conference Call and Live Webcast To participate in the live conference call, please dial +1 (929) 272-1574 (U.S. Local / International 1); +1 (857) 999-3259 (U.S. Local / International 2); +1 (888) 700-7550 (U.S. Toll Free), enter Conference ID: 05905 and request to be joined...

PRESS RELEASE Global Bioenergies: takeover bid deadline extendedto 18 July 2025 Evry, 10 July 2025 – 05:45 p.m.: Potential buyers of Global Bioenergies’ activities expressed their interest yesterday at noon at the deadline that had been set. Two offers and three letters of intent have been sent to Maître Joanna Rousselet1. The candidates have expressed a wish for more time to conduct their study. The date for submission of preliminary bids has therefore been postponed to 18 July 2025 at noon. Postponing will potentially allow other parties to position themselves. The review hearing at which potential final offers would be presented to the Evry Commercial Court could take place in September or October. As a reminder, the pre-pack sale only provides for the sale of the Company’s assets. Global Bioenergies’ shares will not...

CHENNAI, India, July 10, 2025 (GLOBE NEWSWIRE) — Sify Technologies Ltd. (Nasdaq: Sify) (the “Company”), a leading integrated information communications technology (or ICT) Solutions, received a letter (the “Notification Letter”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) on July 8, 2025 notifying the Company that it had regained compliance with the continued listing requirements under Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2) (the “Rules”), requiring the majority of the Board to be composed of independent directors and the Audit Committee to comprise at least three independent directors, respectively. The Company had previously notified Nasdaq on May 21, 2025, that, consequent to the resignation of Dr. Ajay Kumar from the Company’s Board of Directors (the “Board”), the Company was in non-compliance...

BETHESDA, Md., July 10, 2025 (GLOBE NEWSWIRE) — Eagle Bancorp, Inc. (the “Company”) (NASDAQ: EGBN), the Bethesda-based holding company for EagleBank, one of the largest community banks in the Washington D.C. area, today announced that it will host a teleconference call for the financial community on July 24, 2025, at 10:00 a.m. (EDT). On this call, Eagle Bancorp Inc.’s Chief Executive Officer Susan Riel and Chief Financial Officer Eric Newell will discuss earnings for the second quarter 2025 financial results. Those results will be released after the close of business on July 23, 2025. Interested parties will need to register at the below-noted URL in order to listen and participate in the call. Once a participant registers with a valid email, they will receive a dial-in phone number and unique PIN number which will be needed to...

Singapore, July 10, 2025 (GLOBE NEWSWIRE) — Delixy Holdings Limited (Nasdaq: DLXY) (the “Company” or “Delixy”), a Singapore-based company engaged in the trading of oil related products, today announced the closing of its initial public offering (the “Offering”) of 2,000,000 ordinary shares, par value US$0.000005 per share, (“Ordinary Shares”), 1,350,000 of which were offered by the Company and 650,000 by the selling shareholders Mega Origin Holdings Limited (as to 325,000 Ordinary Shares) and Novel Majestic Limited (as to 325,000 Ordinary Shares) (the “Selling Shareholders”), at a public offering price of US$4.00 per Ordinary Share, raising total gross proceeds of US$8 million in the aggregate to the Company and Selling Shareholders. The Ordinary Shares began trading on the Nasdaq Capital Market on July 9, 2025 under the ticker...

ROCKVILLE, Md. and SUZHOU, China, July 10, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that its proprietary novel Bcl-2 selective inhibitor lisaftoclax (APG-2575) has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors, which makes lisaftoclax the first Bcl-2 inhibitor receiving conditional approval and marketing authorization for the treatment of patients with CLL/SLL in China, and the second Bcl-2 inhibitor approved globally. Lisaftoclax is a proprietary, novel orally...